CN113735834B - 普那布林组合物 - Google Patents

普那布林组合物 Download PDF

Info

Publication number
CN113735834B
CN113735834B CN202110926846.8A CN202110926846A CN113735834B CN 113735834 B CN113735834 B CN 113735834B CN 202110926846 A CN202110926846 A CN 202110926846A CN 113735834 B CN113735834 B CN 113735834B
Authority
CN
China
Prior art keywords
plinabulin
composition
monohydrate
mixture
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110926846.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN113735834A (zh
Inventor
黄岚
阿尼路达·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57757489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113735834(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Priority to CN202110926846.8A priority Critical patent/CN113735834B/zh
Publication of CN113735834A publication Critical patent/CN113735834A/zh
Application granted granted Critical
Publication of CN113735834B publication Critical patent/CN113735834B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/004—Fractional crystallisation; Fractionating or rectifying columns
    • B01D9/0045—Washing of crystals, e.g. in wash columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D2009/0086—Processes or apparatus therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202110926846.8A 2015-07-13 2016-07-11 普那布林组合物 Active CN113735834B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110926846.8A CN113735834B (zh) 2015-07-13 2016-07-11 普那布林组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562191990P 2015-07-13 2015-07-13
US62/191,990 2015-07-13
CN202110926846.8A CN113735834B (zh) 2015-07-13 2016-07-11 普那布林组合物
PCT/US2016/041773 WO2017011399A1 (en) 2015-07-13 2016-07-11 Plinabulin compositions
CN201680051286.3A CN108026075B (zh) 2015-07-13 2016-07-11 普那布林组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680051286.3A Division CN108026075B (zh) 2015-07-13 2016-07-11 普那布林组合物

Publications (2)

Publication Number Publication Date
CN113735834A CN113735834A (zh) 2021-12-03
CN113735834B true CN113735834B (zh) 2023-06-13

Family

ID=57757489

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910023460.9A Active CN109516981B (zh) 2015-07-13 2016-07-11 普那布林组合物
CN201680051286.3A Active CN108026075B (zh) 2015-07-13 2016-07-11 普那布林组合物
CN202110926846.8A Active CN113735834B (zh) 2015-07-13 2016-07-11 普那布林组合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201910023460.9A Active CN109516981B (zh) 2015-07-13 2016-07-11 普那布林组合物
CN201680051286.3A Active CN108026075B (zh) 2015-07-13 2016-07-11 普那布林组合物

Country Status (21)

Country Link
US (5) US10155748B2 (enExample)
EP (2) EP4011878A1 (enExample)
JP (2) JP6969848B2 (enExample)
KR (1) KR102680823B1 (enExample)
CN (3) CN109516981B (enExample)
AU (2) AU2016291708B2 (enExample)
BR (1) BR112018000229A2 (enExample)
CA (1) CA2991059C (enExample)
CL (1) CL2018000098A1 (enExample)
CO (1) CO2018000350A2 (enExample)
DK (1) DK3334726T3 (enExample)
EC (1) ECSP18010481A (enExample)
ES (1) ES2910035T3 (enExample)
IL (1) IL256559B2 (enExample)
MX (1) MX376122B (enExample)
MY (1) MY181892A (enExample)
NZ (1) NZ778077A (enExample)
PE (1) PE20180528A1 (enExample)
PH (1) PH12018500071A1 (enExample)
SG (1) SG10202108194XA (enExample)
WO (1) WO2017011399A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078529A1 (zh) 2022-10-11 2024-04-18 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102623404B1 (ko) 2015-03-06 2024-01-11 비욘드스프링 파마수티컬스, 인코포레이티드. 뇌 종양 치료 방법
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
US10851086B2 (en) 2016-08-12 2020-12-01 Marine Biomedical Research Institute Of Qingdao Co., Ltd. Polycrystalline form of dehydrophenylahistin-like compound, and manufacturing and purification method and application thereof
CN107011331A (zh) * 2016-08-12 2017-08-04 青岛海洋生物医药研究院股份有限公司 脱氢苯基阿夕斯丁类化合物的多晶型及其制备方法
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
US11434225B2 (en) 2017-08-03 2022-09-06 Pliva Hrvatska D.O.O. Salts and solid state forms of plinabulin
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2022216908A1 (en) 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
MX2024009821A (es) * 2022-02-10 2024-09-18 Beyondspring Pharmaceuticals Inc Formulaciones estables de plinabulina y metodos para su preparacion y uso.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684955A (zh) * 2002-08-02 2005-10-19 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
CN1934101A (zh) * 2004-02-04 2007-03-21 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
CN101633655A (zh) * 2002-08-02 2010-01-27 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (enExample) 1973-05-11 1975-01-30
ZA818741B (en) 1980-12-18 1983-07-27 Wellcome Found Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
DE69306545T2 (de) 1992-10-01 1997-04-03 Wellcome Found Tucaresol als Mittel zur Immunopotentierung
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
EP0674510B1 (en) 1992-11-27 1998-08-05 Napro Biotherapeutics, Inc. Injectable composition comprising paclitaxel
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
EP2201945B1 (en) 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
CN1173946C (zh) 1998-01-29 2004-11-03 阿温蒂斯药物公司 制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
US6333323B1 (en) 1998-03-26 2001-12-25 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
BR0017067A (pt) 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
ATE417614T1 (de) 2000-05-09 2009-01-15 Angiorx Corp Piperazindion-verbindungen
JP2004518731A (ja) 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 三環式ｃｒｆレセプターアンタゴニスト
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
US20040176372A1 (en) 2002-03-01 2004-09-09 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
UA81628C2 (uk) 2002-05-17 2008-01-25 Авентіс Фарма С.А. Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
JP2007520565A (ja) * 2004-02-04 2007-07-26 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成
EP1740593B1 (en) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
JP4559240B2 (ja) 2005-01-13 2010-10-06 株式会社エヌ・ティ・ティ・ドコモ 移動通信システム、無線基地局、無線回線制御局及び電力制御方法
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
EP2335733B1 (en) 2006-01-18 2014-08-06 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
MX2009008620A (es) 2007-02-15 2009-10-22 Mannkind Corp Un metodo para mejorar la respuesta de celulas t.
ES2389828T3 (es) 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
AU2009204194A1 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CA2749786A1 (en) 2009-01-16 2010-07-22 Jason Benjamin Bock New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI483938B (zh) 2009-08-10 2015-05-11 Univ Texas 以內皮素受體抑制劑處理星狀腫瘤細胞
JP5855568B2 (ja) 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
MX2012004721A (es) 2009-10-23 2012-06-25 Mannkind Corp Inmunoterapia de cancer y metodo de tratamiento.
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
WO2011109625A1 (en) 2010-03-03 2011-09-09 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP2576514A1 (en) 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20120214679A1 (en) 2010-11-29 2012-08-23 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
CN104024851A (zh) 2011-11-28 2014-09-03 加拿大国家研究委员会 针对癌症的紫杉醇反应标志物
US20150004175A1 (en) 2011-12-13 2015-01-01 Yale University Compositions and Methods for Reducing CTL Exhaustion
US9271999B2 (en) 2012-05-09 2016-03-01 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
CN111139256A (zh) 2013-02-20 2020-05-12 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
AU2013402794B2 (en) 2013-10-11 2020-02-27 Beyondspring Inc. Cancer treatment with combination of plinabulin and taxane
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
AU2014346788B8 (en) 2013-11-06 2021-01-28 Arizona Board Of Regents On Behalf Of The Unviersity Of Arizona Method for subtyping lymphoma types by means of expression profiling
CN104796448B (zh) 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
AU2016219204B2 (en) 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
KR102623404B1 (ko) 2015-03-06 2024-01-11 비욘드스프링 파마수티컬스, 인코포레이티드. 뇌 종양 치료 방법
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
EP3359692A4 (en) 2015-10-05 2019-05-01 Cedars-Sinai Medical Center METHOD FOR CLASSIFYING AND TREATING CANCER
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
SG11201908420WA (en) 2017-03-13 2019-10-30 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
JP2021512121A (ja) 2018-02-01 2021-05-13 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法
WO2019232257A1 (en) 2018-06-01 2019-12-05 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
MX2021001762A (es) 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684955A (zh) * 2002-08-02 2005-10-19 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
CN101633655A (zh) * 2002-08-02 2010-01-27 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成
CN1934101A (zh) * 2004-02-04 2007-03-21 尼瑞斯药品公司 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024078529A1 (zh) 2022-10-11 2024-04-18 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Also Published As

Publication number Publication date
AU2016291708B2 (en) 2020-12-24
US20240425485A1 (en) 2024-12-26
NZ739083A (en) 2024-11-29
MY181892A (en) 2021-01-12
CL2018000098A1 (es) 2018-07-20
US20200277280A1 (en) 2020-09-03
US20220169635A1 (en) 2022-06-02
KR20180027563A (ko) 2018-03-14
PE20180528A1 (es) 2018-03-19
PH12018500071B1 (en) 2018-07-23
US10155748B2 (en) 2018-12-18
CN108026075B (zh) 2021-06-29
CA2991059C (en) 2024-01-16
BR112018000229A2 (pt) 2018-09-04
PH12018500071A1 (en) 2018-07-23
CN109516981A (zh) 2019-03-26
JP2021181497A (ja) 2021-11-25
ECSP18010481A (es) 2018-04-30
US20180194749A1 (en) 2018-07-12
MX2018000451A (es) 2018-05-07
US11254657B2 (en) 2022-02-22
CO2018000350A2 (es) 2018-06-12
IL256559A (en) 2018-02-28
AU2021201784A1 (en) 2021-04-15
AU2016291708A1 (en) 2018-02-01
US20190106410A1 (en) 2019-04-11
AU2021201784B2 (en) 2022-12-01
HK1251559A1 (zh) 2019-02-01
JP6969848B2 (ja) 2021-11-24
EP3334726A1 (en) 2018-06-20
JP2018520178A (ja) 2018-07-26
NZ778077A (en) 2024-11-29
MX376122B (es) 2025-03-07
SG10202108194XA (en) 2021-09-29
EP4011878A1 (en) 2022-06-15
CA2991059A1 (en) 2017-01-19
IL256559B2 (en) 2023-07-01
EP3334726A4 (en) 2019-04-17
KR102680823B1 (ko) 2024-07-03
WO2017011399A1 (en) 2017-01-19
CN108026075A (zh) 2018-05-11
ES2910035T3 (es) 2022-05-11
US10550104B2 (en) 2020-02-04
US12024501B2 (en) 2024-07-02
IL256559B1 (en) 2023-03-01
EP3334726B1 (en) 2022-03-16
CN113735834A (zh) 2021-12-03
DK3334726T3 (da) 2022-05-16
CN109516981B (zh) 2019-10-22

Similar Documents

Publication Publication Date Title
CN113735834B (zh) 普那布林组合物
US20090181990A1 (en) Stable amorphous form of pemetrexed disodium
US11286259B2 (en) Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
ES2949662T3 (es) Compuesto farmacéutico, sales del mismo, formulaciones del mismo y métodos de fabricación y uso del mismo
US12011442B2 (en) Solid-state forms of Abemaciclib, their use and preparation
RU2773843C1 (ru) Композиции плинабулина
HK40006402B (en) Plinabulin compositions
HK40006402A (en) Plinabulin compositions
HK1251559B (zh) 普那布林组合物
KR102903080B1 (ko) 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법
HK40033890A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant